Cogent Biosciences, Inc. (COGT) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $33.33: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Cogent Biosciences is a clinical-stage biotech developing bezuclastinib, a selective KIT inhibitor, for Systemic Mastocytosis and GIST. The company submitted its first NDA for NonAdvSM in December 2025 and initiated the GIST NDA submission in January 2026; a U.S. commercial... Read more
Sell if holding. Engine safety override at $33.33: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 5.2/10, moderate confidence.
Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
About Cogent Biosciences, Inc.
About Cogent Biosciences, Inc.
Cogent Biosciences reported positive top-line results from all three registrational trials for bezuclastinib in 2025: SUMMIT (NonAdvSM), APEX (AdvSM), and PEAK (GIST). The company submitted its first NDA in December 2025 (NonAdvSM), initiated the GIST NDA submission in January 2026, and targets an AdvSM NDA in the first half of 2026. The FDA granted Breakthrough Therapy Designation for bezuclastinib in NonAdvSM in October 2025 and for second-line GIST in January 2026. A U.S. commercial launch is planned for the second half of 2026.
Cogent Biosciences has no product revenue; the company funds operations through equity financing and plans to commercialize bezuclastinib in SM and GIST following regulatory approval. Bezuclastinib is licensed exclusively from Plexxikon Inc., a Daiichi Sankyo subsidiary, under a 2020 license agreement that requires tiered royalties ranging from low- to high-single-digit percentages on annual net sales, aggregate development milestone payments of up to $7.5 million (the first $2.5 million paid in June 2022, $5.0 million triggered in Q4 2025), and regulatory milestones of up to $25.0 million (an additional $15.0 million may become payable within twelve months). The company is building an internal commercial organization to market bezuclastinib in the United States. Early-stage pipeline assets include CGT4859 (FGFR2/3 inhibitor, Phase 1 enrolling), CGT4255 (CNS-penetrant ErbB2 inhibitor, Phase 1 initiated Q4 2025), and CGT6297 (PI3Kα inhibitor, IND submitted Q4 2025). Preclinical KRAS and JAK2 V617F programs have IND submissions planned for 2026.
Show full overview
Cogent's valuation is essentially a single NDA binary: bezuclastinib is the only program at a regulatory stage and the source of all planned near-term revenue. The PEAK trial demonstrated median PFS of 16.5 months versus 9.2 months for sunitinib monotherapy in second-line GIST, reducing the risk of progression or death by 50%. However, there is no guarantee of regulatory approval for any indication, and even an approved bezuclastinib would face competition from Blueprint Medicines' avapritinib (a Sanofi company) and Novartis AG's midostaurin in AdvSM, with market size estimates inherently uncertain for rare-disease indications.
See also: Healthcare · Biotechnology
From Cogent Biosciences, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-14Recent Developments — Cogent Biosciences, Inc.
Latest news
- NEWS Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European — benzinga Jun 12, 2026 positive
- NEWS Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target — benzinga May 29, 2026 positive
- NEWS Cogent Biosciences Says FDA Accepts NDA For Bezuclastinib In Combination With Sunitinib For Patients With GIST With PDUF — benzinga May 28, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55 — benzinga May 6, 2026 positive
- NEWS Cogent Biosciences Q1 EPS $(0.53) Beats $(0.56) Estimate — benzinga May 5, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinebezuclastinib program10-K Item 1A: 'Our business is highly dependent on the success of our bezuclastinib program and our ability to discover and develop additional product candidates.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $33.33: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $30.78. Score 5.2/10, moderate confidence.
Take-profit target: $47.20 (+42.6% upside). Prior stop was $30.78. Stop-loss: $30.78.
Concentration risk — Pipeline: bezuclastinib program; Quality below floor (1.5 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.0), Material insider selling (5 sells, 0.10% of cap).
Cogent Biosciences, Inc. trades at a P/E of N/A (forward -34.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
19 analysts cover COGT with a consensus score of 4.3/5. Average price target: $54.
What does Cogent Biosciences, Inc. do?Cogent Biosciences is a clinical-stage biotech developing bezuclastinib, a selective KIT inhibitor, for Systemic...
Cogent Biosciences is a clinical-stage biotech developing bezuclastinib, a selective KIT inhibitor, for Systemic Mastocytosis and GIST. The company submitted its first NDA for NonAdvSM in December 2025 and initiated the GIST NDA submission in January 2026; a U.S. commercial launch in the second half of 2026 is planned pending regulatory approval. Bezuclastinib is exclusively in-licensed from Plexxikon Inc. with mid- to high-single-digit royalties on net sales.